f Capivasertib: First Approved AKT inhibitor for the Treatment of Patients with Breast Cancer

References

1. Bray F. Laversanne M. Sung H. Ferlay J. Siegel R.L. Soerjomataram I. Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024 74 3 229 263 10.3322/caac.21834 38572751
   [Google Scholar]
2. De S.K. Fundamental of cancer detection, treatment, and prevention. Wiley 2022 151 191 10.1002/9783527838561.ch6
   [Google Scholar]
3. Moo T.A. Sanford R. Dang C. Morrow M. Overview of Breast Cancer Therapy. PET Clin. 2018 13 3 339 354 10.1016/j.cpet.2018.02.006 30100074
   [Google Scholar]
4. Trayes K.P. Cokenakes S.E.H. Breast Cancer Treatment. Am. Fam. Physician 2021 104 2 171 178 34383430
   [Google Scholar]
5. Singh A. Mishra R. Mazumder A. Breast cancer and its therapeutic targets: A comprehensive review. Chem. Biol. Drug Des. 2024 103 1 e14384 10.1111/cbdd.14384 37919259
   [Google Scholar]
6. Barile E. De S.K. Carlson C.B. Chen V. Knutzen C. Riel-Mehan M. Yang L. Dahl R. Chiang G. Pellecchia M. Design, synthesis, and structure-activity relationships of 3-ethynyl-1H-indazoles as inhibitors of the phosphatidylinositol 3-kinase signaling pathway. J. Med. Chem. 2010 53 23 8368 8375 10.1021/jm100825h 21062009
   [Google Scholar]
7. Ibanez K.R. Huang T.T. Lee J.M. Combination therapy approach to overcome the resistance to PI3K pathway inhibitors in gynecological cancers. Cells 2024 13 12 1064 10.3390/cells13121064 38920692
   [Google Scholar]
8. Zhang H. Jiang R. Zhu J. Sun K. Huang Y. Zhou H. Zheng Y. Wang X. PI3K/AKT/mTOR signaling pathway: An important driver and therapeutic target in triple-negative breast cancer. Breast Cancer 2024 31 4 539 551 10.1007/s12282‑024‑01567‑5 38630392
   [Google Scholar]
9. Browne I.M. André F. Chandarlapaty S. Carey L.A. Turner N.C. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024 25 4 e139 e151 10.1016/S1470‑2045(23)00676‑9 38547898
   [Google Scholar]
10. Wylaź M. Kaczmarska A. Pajor D. Hryniewicki M. Gil D. Dulińska-Litewka J. Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer. Biomed. Pharmacother. 2023 168 115676 10.1016/j.biopha.2023.115676 37832401
    [Google Scholar]
11. Selvam T.P. Karthick V. Kumar P.V. Ali M.A. Synthesis and structure-activity relationship study of 2-(substituted benzylidene)-7-(4-fluorophenyl)-5-(furan-2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one derivatives as anticancer agents. Drug Discov. Ther. 2012 6 4 198 204 10.5582/ddt.2012.v6.4.198 23006990
    [Google Scholar]
12. Browne I.M. Okines A.F.C. Resistance to targeted inhibitors of the PI3K/AKT/mTOR pathway in advanced oestrogen-receptor-positive breast cancer. Cancers (Basel) 2024 16 12 2259 10.3390/cancers16122259 38927964
    [Google Scholar]
13. Luboff A.J. DeRemer D.L. Capivasertib: A novel AKT inhibitor approved for hormone-receptor-positive, HER-2-negative metastatic breast cancer. Ann. Pharmacother. 2024 58 12 1229 1237 Epub ahead of print 10.1177/10600280241241531 38566315
    [Google Scholar]
14. López-Knowles E. O’Toole S.A. McNeil C.M. Millar E.K.A. Qiu M.R. Crea P. Daly R.J. Musgrove E.A. Sutherland R.L. PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality. Int. J. Cancer 2010 126 5 1121 1131 10.1002/ijc.24831 19685490
    [Google Scholar]
15. Csolle M.P. Ooms L.M. Papa A. Mitchell C.A. PTEN and other PtdIns(3,4,5)P3 lipid phosphatases in breast cancer. Int. J. Mol. Sci. 2020 21 23 9189 10.3390/ijms21239189 33276499
    [Google Scholar]
16. Turner N.C. Oliveira M. Howell S.J. Dalenc F. Cortes J. Gomez Moreno H.L. Hu X. Jhaveri K. Krivorotko P. Loibl S. Morales Murillo S. Okera M. Park Y.H. Sohn J. Toi M. Tokunaga E. Yousef S. Zhukova L. de Bruin E.C. Grinsted L. Schiavon G. Foxley A. Rugo H.S. Capivasertib in hormone receptor–positive advanced breast cancer. N. Engl. J. Med. 2023 388 22 2058 2070 10.1056/NEJMoa2214131 37256976
    [Google Scholar]
17. Smyth L.M. Tamura K. Oliveira M. Ciruelos E.M. Mayer I.A. Sablin M.P. Biganzoli L. Ambrose H.J. Ashton J. Barnicle A. Cashell D.D. Corcoran C. de Bruin E.C. Foxley A. Hauser J. Lindemann J.P.O. Maudsley R. McEwen R. Moschetta M. Pass M. Rowlands V. Schiavon G. Banerji U. Scaltriti M. Taylor B.S. Chandarlapaty S. Baselga J. Hyman D.M. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 E17K-mutant, er-positive metastatic breast cancer. Clin. Cancer Res. 2020 26 15 3947 3957 10.1158/1078‑0432.CCR‑19‑3953 32312891
    [Google Scholar]
18. Smyth L.M. Batist G. Meric-Bernstam F. Kabos P. Spanggaard I. Lluch A. Jhaveri K. Varga A. Wong A. Schram A.M. Ambrose H. Carr T.H. de Bruin E.C. Salinas-Souza C. Foxley A. Hauser J. Lindemann J.P.O. Maudsley R. McEwen R. Moschetta M. Nikolaou M. Schiavon G. Razavi P. Banerji U. Baselga J. Hyman D.M. Chandarlapaty S. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ Breast Cancer 2021 7 1 44 10.1038/s41523‑021‑00251‑7 33863913
    [Google Scholar]
19. Andrikopoulou A. Chatzinikolaou S. Panourgias E. Kaparelou M. Liontos M. Dimopoulos M.A. Zagouri F. The emerging role of capivasertib in breast cancer. Breast 2022 63 157 167 10.1016/j.breast.2022.03.018 35398754
    [Google Scholar]
20. Addie M. Ballard P. Buttar D. Crafter C. Currie G. Davies B.R. Debreczeni J. Dry H. Dudley P. Greenwood R. Johnson P.D. Kettle J.G. Lane C. Lamont G. Leach A. Luke R.W.A. Morris J. Ogilvie D. Page K. Pass M. Pearson S. Ruston L. Discovery of 4-Amino- N -[(1 S )-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7 H -pyrrolo[2,3- d ]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of akt kinases. J. Med. Chem. 2013 56 5 2059 2073 10.1021/jm301762v 23394218
    [Google Scholar]
21. Wang Y.T. Yang P.C. Zhang Y.F. Sun J.F. Synthesis and clinical application of new drugs approved by FDA in 2023. Eur. J. Med. Chem. 2024 265 116124 10.1016/j.ejmech.2024.116124 38183778
    [Google Scholar]
22. Miller C. Wild M. Zhang Z Sommavilla R. Shanahan D. Bailey C. Gränfors M. Bragg R.A. Dong J. Sidhu S. Cullberg M. A Phase I study to determine the absolute bioavailability and absorption, distribution, metabolism, and excretion of capivasertib in healthy male participants. Drug Metab Dispos. 2024 52 9 939 948 10.1124/dmd.124.001636
    [Google Scholar]
23. Fernandez-Teruel C. Cullberg M. Eberlein C. Barry S.T. Zhou D. Population pharmacokinetics of capivasertib in patients with advanced or metastatic solid tumours. Clin. Pharmacokinet. 2024 63 8 1191 1204 10.1007/s40262‑024‑01407‑x 39127854
    [Google Scholar]
24. De S.K. Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome. Front. Pharmacol. 2024 15 1337436 10.3389/fphar.2024.1337436 38410131
    [Google Scholar]
25. Rescigno P. Porta N. Finneran L. Riisnaes R. Figueiredo I. Carreira S. Flohr P. Miranda S. Bertan C. Ferreira A. Crespo M. Rodrigues D.N. Gurel B. Nobes J. Crabb S. Malik Z. Ralph C. McGovern U. Hoskin P. Jones R.J. Birtle A. Gale J. Sankey P. Jain S. McLaren D. Chadwick E. Espinasse A. Hall E. de Bono J. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. Eur. J. Cancer 2024 205 114103 10.1016/j.ejca.2024.114103 38729054
    [Google Scholar]
26. Eberlein C. Williamson S.C. Hopcroft L. Ros S. Moss J.I. Kerr J. van Weerden W.M. de Bruin E.C. Dunn S. Willis B. Ross S.J. Rooney C. Barry S.T. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br. J. Cancer 2024 130 8 1377 1387 10.1038/s41416‑024‑02614‑w 38396173
    [Google Scholar]
27. Crabb S.J. Griffiths G. Marwood E. Dunkley D. Downs N. Martin K. Light M. Northey J. Wilding S. Whitehead A. Shaw E. Birtle A.J. Bahl A. Elliott T. Westbury C. Sundar S. Robinson A. Jagdev S. Kumar S. Rooney C. Salinas-Souza C. Stephens C. Khoo V. Jones R.J. Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: A randomized, placebo-controlled phase ii trial (ProCAID). J. Clin. Oncol. 2021 39 3 190 201 10.1200/JCO.20.01576 33326257
    [Google Scholar]
28. Yap T.A. Kristeleit R. Michalarea V. Pettitt S.J. Lim J.S.J. Carreira S. Roda D. Miller R. Riisnaes R. Miranda S. Figueiredo I. Rodrigues D.N. Ward S. Matthews R. Parmar M. Turner A. Tunariu N. Chopra N. Gevensleben H. Turner N.C. Ruddle R. Raynaud F.I. Decordova S. Swales K.E. Finneran L. Hall E. Rugman P. Lindemann J.P.O. Foxley A. Lord C.J. Banerji U. Plummer R. Basu B. Lopez J.S. Drew Y. de Bono J.S. Phase I. Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 - and non– BRCA1/2 -mutant cancers. Cancer Discov. 2020 10 10 1528 1543 10.1158/2159‑8290.CD‑20‑0163 32532747
    [Google Scholar]
29. Westin S.N. Labrie M. Litton J.K. Blucher A. Fang Y. Vellano C.P. Marszalek J.R. Feng N. Ma X. Creason A. Fellman B. Yuan Y. Lee S. Kim T.B. Liu J. Chelariu-Raicu A. Chen T.H. Kabil N. Soliman P.T. Frumovitz M. Schmeler K.M. Jazaeri A. Lu K.H. Murthy R. Meyer L.A. Sun C.C. Sood A.K. Coleman R.L. Mills G.B. Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer. Clin. Cancer Res. 2021 27 23 6354 6365 10.1158/1078‑0432.CCR‑21‑1656 34518313
    [Google Scholar]